CD135 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "CD135" in English language version.

Last modified: 21:46:35, 8 September 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

1313nih.gov

5^th place

88doi.org

2^nd place

64web.archive.org

1^st place

62ensembl.org

630^th place

326^th place

43fda.gov

470^th place

329^th place

21sabiosciences.com

low place

11atlasgeneticsoncology.org

low place

11cancertherapyadvisor.com

low place

11semanticscholar.org

15^th place

8^th place

11adsabs.harvard.edu

14^th place

9^th place

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

ui.adsabs.harvard.edu

Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. (April 2012). "Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia". Nature. 485 (7397): 260–3. Bibcode:2012Natur.485..260S. doi:10.1038/nature11016. PMC 3390926. PMID 22504184.

atlasgeneticsoncology.org (Global: low place; English: low place)

Huret J-L. "FLT3 (FMS-like tyrosine kinase 3)". Atlas of Genetics and Cytogenetics in Oncology and Haematology. University Hospital of Poitiers.

cancertherapyadvisor.com (Global: low place; English: low place)

"Gilteritinib Granted Orphan Drug Status for Acute Myeloid Leukemia". Cancer Therapy Advisor. 20 July 2017.

doi.org (Global: 2^nd place; English: 2^nd place)

Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T (April 2001). "Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies". Blood. 97 (8): 2434–9. doi:10.1182/blood.V97.8.2434. PMID 11290608.
Verstraete K, Vandriessche G, Januar M, Elegheert J, Shkumatov AV, Desfosses A, Van Craenenbroeck K, Svergun DI, Gutsche I, Vergauwen B, Savvides SN (February 2011). "Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex". Blood. 118 (1): 60–68. doi:10.1182/blood-2011-01-329532. PMID 21389326.
Mooney CJ, Cunningham A, Tsapogas P, Toellner KM, Brown G (May 2017). "Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment". Int J Mol Sci. 18 (5): 1037. doi:10.3390/ijms18051037. PMC 5454949. PMID 28498310.
Chew S, Mackey MC, Jabbour E (2020). "Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation". Review. Therapeutic Advances in Hematology. 11 2040620720930614. doi:10.1177/2040620720930614. PMC 7271272. PMID 32547718.
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. (October 2019). "FLT3-Mutated AML". The New England Journal of Medicine. 381 (18): 1728–1740. doi:10.1056/NEJMoa1902688. PMID 31665578.
Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A (June 2009). "Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation". Blood. 113 (26): 6567–71. doi:10.1182/blood-2009-03-208298. PMID 19389879. S2CID 206878993.
Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M (February 2008). "Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia". J. Natl. Cancer Inst. 100 (3): 184–98. doi:10.1093/jnci/djm328. PMID 18230792.
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. (April 2012). "Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia". Nature. 485 (7397): 260–3. Bibcode:2012Natur.485..260S. doi:10.1038/nature11016. PMC 3390926. PMID 22504184.

ensembl.org (Global: 630^th place; English: 326^th place)

may2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000122025 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000042817 – Ensembl, May 2017

fda.gov (Global: 470^th place; English: 329^th place)

"FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutatation". Drugs. FDA. December 14, 2018. Archived from the original on September 28, 2019. Retrieved July 21, 2023.
"FDA approves quizartinib for newly diagnosed acute myeloid leukemia". Drugs. FDA. July 20, 2023. Archived from the original on July 20, 2023. Retrieved July 21, 2023.
Office of the Commissioner. "Press Announcements - FDA approves new combination treatment for acute myeloid leukemia". www.fda.gov. Archived from the original on April 28, 2017. Retrieved 2017-05-04.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T (April 2001). "Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies". Blood. 97 (8): 2434–9. doi:10.1182/blood.V97.8.2434. PMID 11290608.
Verstraete K, Vandriessche G, Januar M, Elegheert J, Shkumatov AV, Desfosses A, Van Craenenbroeck K, Svergun DI, Gutsche I, Vergauwen B, Savvides SN (February 2011). "Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex". Blood. 118 (1): 60–68. doi:10.1182/blood-2011-01-329532. PMID 21389326.
Mooney CJ, Cunningham A, Tsapogas P, Toellner KM, Brown G (May 2017). "Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment". Int J Mol Sci. 18 (5): 1037. doi:10.3390/ijms18051037. PMC 5454949. PMID 28498310.
Chew S, Mackey MC, Jabbour E (2020). "Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation". Review. Therapeutic Advances in Hematology. 11 2040620720930614. doi:10.1177/2040620720930614. PMC 7271272. PMID 32547718.
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. (October 2019). "FLT3-Mutated AML". The New England Journal of Medicine. 381 (18): 1728–1740. doi:10.1056/NEJMoa1902688. PMID 31665578.
Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A (June 2009). "Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation". Blood. 113 (26): 6567–71. doi:10.1182/blood-2009-03-208298. PMID 19389879. S2CID 206878993.
Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M (February 2008). "Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia". J. Natl. Cancer Inst. 100 (3): 184–98. doi:10.1093/jnci/djm328. PMID 18230792.
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. (April 2012). "Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia". Nature. 485 (7397): 260–3. Bibcode:2012Natur.485..260S. doi:10.1038/nature11016. PMC 3390926. PMID 22504184.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Mooney CJ, Cunningham A, Tsapogas P, Toellner KM, Brown G (May 2017). "Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment". Int J Mol Sci. 18 (5): 1037. doi:10.3390/ijms18051037. PMC 5454949. PMID 28498310.
Chew S, Mackey MC, Jabbour E (2020). "Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation". Review. Therapeutic Advances in Hematology. 11 2040620720930614. doi:10.1177/2040620720930614. PMC 7271272. PMID 32547718.
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. (April 2012). "Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia". Nature. 485 (7397): 260–3. Bibcode:2012Natur.485..260S. doi:10.1038/nature11016. PMC 3390926. PMID 22504184.

sabiosciences.com (Global: low place; English: low place)

"FLT3 Signaling". Pathway Central. SABiosciences. Archived from the original on 2017-11-11. Retrieved 2012-12-18.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A (June 2009). "Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation". Blood. 113 (26): 6567–71. doi:10.1182/blood-2009-03-208298. PMID 19389879. S2CID 206878993.

web.archive.org (Global: 1^st place; English: 1^st place)

"FLT3 Signaling". Pathway Central. SABiosciences. Archived from the original on 2017-11-11. Retrieved 2012-12-18.
"FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutatation". Drugs. FDA. December 14, 2018. Archived from the original on September 28, 2019. Retrieved July 21, 2023.
"FDA approves quizartinib for newly diagnosed acute myeloid leukemia". Drugs. FDA. July 20, 2023. Archived from the original on July 20, 2023. Retrieved July 21, 2023.
Office of the Commissioner. "Press Announcements - FDA approves new combination treatment for acute myeloid leukemia". www.fda.gov. Archived from the original on April 28, 2017. Retrieved 2017-05-04.

CD135 (English Wikipedia)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

atlasgeneticsoncology.org (Global: low place; English: low place)

cancertherapyadvisor.com (Global: low place; English: low place)

doi.org (Global: 2nd place; English: 2nd place)

ensembl.org (Global: 630th place; English: 326th place)

may2017.archive.ensembl.org

fda.gov (Global: 470th place; English: 329th place)

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

sabiosciences.com (Global: low place; English: low place)

semanticscholar.org (Global: 15th place; English: 8th place)

api.semanticscholar.org

web.archive.org (Global: 1st place; English: 1st place)

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

ensembl.org (Global: 630^th place; English: 326^th place)

fda.gov (Global: 470^th place; English: 329^th place)

nih.gov (Global: 5^th place; English: 5^th place)

semanticscholar.org (Global: 15^th place; English: 8^th place)

web.archive.org (Global: 1^st place; English: 1^st place)